Serum Levels of Interleukin 10 (IL-10) in Patients with Type 2 Diabetes

Dear Editor,

The frequency of diabetes mellitus is increasing and it is expected that this disorder will affect 300 million people in 2025.\(^1\) It has been suggested that diabetes is an immune dependent disease in which the pattern of cytokine expression is changed.\(^2\) As an example, in type 2 diabetes, the monocytes of peripheral blood produce more inflammatory cytokines than those from normal patients.\(^2\) The association of IL-10 in immunological disorders such as multiple sclerosis,\(^3,4\) nephrotic syndrome\(^5,6\) and type-1 diabetes\(^7,8\) is well established. The key role of IL-10 is to work as the main inhibitory cytokine against the action of inflammatory cytokines such as IL-12. Based on evidence suggesting that immune responses may be important in inducing type 2 diabetes,\(^9\) this study was designed to evaluate serum levels of IL-10 in type 2 diabetes. Peripheral blood samples were collected from 131 type 2 diabetic patients and 120 healthy controls. The patient and control groups were matched for sex and age. IL-10 serum level was measured using ELISA kit (eBioscience, Spain) in both groups. The differences in variables were analyzed by student t tests. Results of our study showed that the mean IL-10 serum level was 9.53±2.27 and 16.11±2.27 pg/ml in type 2 diabetic patients and control groups, respectively. Statistical analysis showed that the difference was significant (p<0.005). Our findings indicated a significant difference between IL-10 serum levels in type 2 diabetic patients compared to healthy controls. Other researchers also showed same results such as Eric VE et al., 2002 who indicated that the serum levels of IL-10 decreased in type 2 diabetic patients compared to controls.\(^10\) Based on this fact, it may be concluded that low serum levels of IL-10 can be considered as a risk factor of type 2 diabetes.

Keywords: Interleukin 10; Type 2 diabetes

Conflict of interest: None declared.

N Yaghini\(^1\), M Mahmoodi\(^1,2,*\), GhR Asadikaram\(^1\), GhH Hassanshahi\(^2\), H Khoramdelazad\(^2\), M Kazemi Arababadi\(^3,4\)

\(^1\)Department of Biochemistry, \(^2\)Molecular-Medicine Research Center, \(^3\)Department of Microbiology, Hematology and Immunology, \(^4\)Infectious and Tropical Disease Research Center, Rafsanjan University of Medical Sciences, Rafsanjan, Iran

*Correspondence: Mehdi Mahmoodi, PhD, Department of Biochemistry, Faculty of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran. Tel: +98-391-5234003-5, +98-913-1914855, Fax: +98-391-5225209, e-mail: mahmoodies@yahoo.com

Received: April 12, 2011 Accepted: July 25, 2011

References
